Alopecia or hair loss could be a possible side effect of Ozempic-like GLP-1 receptor agonists, particularly semaglutide and tirzepatide, research has found. The findings, published in The British Medical Journal, show that GLP-1RA users were 37 per cent more likely to develop alopecia than SGLT-2 inhibitor users -- diabetes drugs which target kidneys to remove extra sugar from urine -- while they had a 68 per cent higher risk, compared to users of DPP-4 inhibitors.
DPP4-inhibitors are another class of drugs which block the DPP-4 enzyme and stimulate insulin release. All the drugs are prescribed as anti-diabetes treatments.
